Table 1.
Baseline clinical and laboratory features.
| Group A | Group B | |
|---|---|---|
| N. of patients | 13 (37.1%) | 22 (62.9%) |
| Age at diagnosis (years) | 12 (8–13) | 8.5 (4–12) |
| Positive SARS-CoV2 swab in the six weeks previous to admission | 84.6% | 31.8% |
| IgG SARS-Cov2 positivity | 100% | 100% |
| Clinical presentation | ||
| Days of fever | 5 (4–6) | 5 (4–6) |
| Conjunctivitis | 53.8% | 81.8% |
| Mucositis | 23.1% | 54.5% |
| Lymphadenopathy | 23.1% | 45.5% |
| Hands and feet erythema/oedema | 7.7% | 18.2% |
| Rash | 46.2% | 50.0% |
| Diarrhea | 61.5% | 50.0% |
| Abdominal pain | 61.5% | 86.4% |
| Hypotensiona | 61.5% | 40.9% |
| Blood exams (at anakinra start) | ||
| Platelets (/mmc3) | 185 (107–189) | 152 (89–187) |
| WBC (/mmc3) | 10,780 (5,020–14,280) | 10,935 (6,155–18,500) |
| Lymphocytes (/mmc3) | 960 (660–980) | 1,710 (760–1,970) |
| Neutrophil (/mmc3) | 9,820 (4,280–13,310) | 7,175 (4,370–17,020) |
| AST (UI/L) | 40 (27–69) | 31 (25–58) |
| ALT (UI/L) | 33 (21–53) | 40 (20–47) |
| Na (mmol/L) | 133 (132–135) | 137 (134–138) |
| Albumin (g/dl) | 3.1 (2.7–3.4) | 2.9 (2.4–3.1) |
| CRP (mg/L) | 293 (212–305) | 86 (17–153) |
| Procalcitonin (ng/ml) | 11.3 (3.5–49.0) | 1 (0.3–12.6) |
| Ferritin (ng/ml) | 974 (419–4,006) | 598 (447–1,366) |
| Cardio-pulmonary alterations (at anakinra start) | ||
| Hypotensiona | 69.2% | 36.4% |
| Need of inotrope support | 69.2% | 0% |
| Ejection fraction ≤50% | 75.0% | 23.8% |
| Pericardial effusion | 44.4% | 38.1% |
| BNP (ng/ml) | – | 49 (7–123) |
| proBNP (ng/ml) | 16,549 (3,247–20,163) | 6,043 (1,405–10,502) |
| CAA | 0% | 9,1% |
| Pleural effusion | 30.8% | 4.5% |
| Need of O2 supplementation | 61.5% | 13.6% |
All the continuous variables are expressed as median and IQR.
MV, mechanical ventilation; NIV, noninvasive ventilation; HFNC, high flow nasal cannula; NC, nasal cannula.
a
Below 5° percentile, according to age, gender, and height adjusted charts (Schwandt et al. Am J Hypertens. 2015).